Key Points
- Insider sale: Kimberly Maersk-Moller sold 58,300 shares on Nov. 6 at an average price of $7.42 for a total of $432,586, trimming her holding by 19.74% to 236,982 shares.
- Recent results and valuation: MiMedx reported (‑$0.03) EPS and $67.69M in quarterly revenue; the stock opened at $7.71, has a market cap of about $1.14B and an average analyst target of $12.00.
- Institutional ownership: Hedge funds and institutional investors own roughly 79.15% of the company, with several funds recently adding to or trimming positions.
MiMedx Group, Inc (NASDAQ:MDXG - Get Free Report) insider Kimberly Maersk-Moller sold 58,300 shares of MiMedx Group stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $7.42, for a total transaction of $432,586.00. Following the completion of the sale, the insider owned 236,982 shares in the company, valued at approximately $1,758,406.44. This trade represents a 19.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
MiMedx Group Stock Up 3.6%
MDXG opened at $7.71 on Tuesday. MiMedx Group, Inc has a twelve month low of $5.79 and a twelve month high of $10.14. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08. The company has a 50-day moving average price of $7.04 and a 200 day moving average price of $6.83. The company has a market cap of $1.14 billion, a PE ratio of 28.56 and a beta of 1.70.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.03) earnings per share (EPS) for the quarter. MiMedx Group had a return on equity of 28.35% and a net margin of 10.38%.The firm had revenue of $67.69 million during the quarter. Sell-side analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.
Hedge Funds Weigh In On MiMedx Group
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Alps Advisors Inc. acquired a new stake in shares of MiMedx Group in the 1st quarter worth $340,000. New York State Common Retirement Fund boosted its position in shares of MiMedx Group by 51.8% during the 1st quarter. New York State Common Retirement Fund now owns 87,781 shares of the company's stock valued at $667,000 after acquiring an additional 29,941 shares during the last quarter. Isthmus Partners LLC grew its holdings in shares of MiMedx Group by 1.1% in the first quarter. Isthmus Partners LLC now owns 310,262 shares of the company's stock valued at $2,358,000 after purchasing an additional 3,455 shares during the period. Allianz Asset Management GmbH acquired a new stake in MiMedx Group during the first quarter worth about $128,000. Finally, Legato Capital Management LLC purchased a new position in MiMedx Group during the first quarter worth about $101,000. Institutional investors and hedge funds own 79.15% of the company's stock.
Analysts Set New Price Targets
MDXG has been the subject of several research reports. Weiss Ratings reiterated a "hold (c)" rating on shares of MiMedx Group in a research report on Wednesday, October 8th. Cantor Fitzgerald lifted their target price on shares of MiMedx Group from $11.00 to $12.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Finally, Wall Street Zen raised shares of MiMedx Group from a "buy" rating to a "strong-buy" rating in a report on Sunday, November 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $12.00.
Check Out Our Latest Stock Report on MiMedx Group
MiMedx Group Company Profile
(
Get Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
